Takeda Pharmaceutical has partnered with Innovation Network Corporation of Japan (INCJ), a Tokyo-headquartered public-private partnership focused on promoting innovation and enhancing business value in Japan, and Medipal Holdings, a Tokyo-headquartered networking group of manufacturers, medical institutions, and retailers, to jointly invest a total of Japanese yen 10 billion ($87 million) to establish a new biotechnology venture company that will be named Scohia Pharma.

Following its launch within Takeda’s Shonan Research Center, Scohia Pharma will sign a license agreement with Takeda for eight of Takeda’s renal, metabolic, and cardiovascular research and development projects, with the goal of initiating operations on April 1, 2017.

Source Takeda Pharmaceutical